Company profile: Selexys Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Selexys Pharmaceuticals
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
NexImmune
HQ: United States
Website
- Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NexImmune company profile →
Dyne Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies for serious muscle diseases, including DYNE-101 for myotonic dystrophy type 1 to reduce mutant DMPK RNA, DYNE-251 for Duchenne muscular dystrophy amenable to exon 51 skipping to enable truncated, functional dystrophin, and DYNE-301 for facioscapulohumeral muscular dystrophy by reducing DUX4 expression; uses its FORCE platform to develop targeted oligonucleotide therapeutics and conducts clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dyne Therapeutics company profile →
ImmunOs Therapeutics
HQ: Switzerland
Website
- Description: Provider of next-generation human immunomodulatory therapeutics. The clinical-stage company develops IOS-1002, an immunotherapy targeting multiple immune-suppressive receptors for solid tumors and hematologic malignancies; an HLA-based platform for biologics against cancer and autoimmune diseases; and antibodies blocking specific HLA molecules for autoimmune conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunOs Therapeutics company profile →
Acceptys
HQ: United States
Website
- Description: Provider of human antibody therapies targeting cancer and infectious diseases, offering anti-cancer and anti-viral human antibodies for lung, pancreatic, gastric, and colon cancers. Founded in 2002 and based in Sparta, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acceptys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Selexys Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Selexys Pharmaceuticals
2.2 - Growth funds investing in similar companies to Selexys Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Selexys Pharmaceuticals
4.2 - Public trading comparable groups for Selexys Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →